Dr Roe speaks with ecancertv at ASH 2016 about genotyping and treatment outcomes for patients with myelodysplastic syndrome with T cell large granular lymphocyte proliferations (LGL).
She describes characterisation of patients by age and risk, with a greater response to lenalidomide from patients without LGL clonal types.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.